Company & Sponsor Intelligence

UCB BIOSCIENCES, Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials4

Recruiting0

Completed4

Countries1

Therapeutic footprint

epilepsy

Indexed studies

NCT00522275Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
epilepsy · United StatesPHASE3

NCT06118255A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
epilepsy · United StatesPHASE3

NCT01118962Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
epilepsy · United StatesPHASE2

NCT01339559Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
epilepsy · United StatesPHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →